DDInter763 DDInter1628
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Flurbiprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Flurbiprofen {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Flurbiprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Flurbiprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) ZNF451
ZNF451 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) upregulates {v} (Gene) CPSF4
CPSF4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) downregulates {v} (Gene) PSMG1
PSMG1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Flurbiprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) regulates {v} (Gene) C2CD2L
C2CD2L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Flurbiprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Flurbiprofen (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Flurbiprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Flurbiprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by ZNF451 (Gene) and ZNF451 (Gene) is upregulated by Ruxolitinib (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) upregulates CPSF4 (Gene) and CPSF4 (Gene) is downregulated by Ruxolitinib (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) downregulates PSMG1 (Gene) and PSMG1 (Gene) is downregulated by Ruxolitinib (Compound)
Flurbiprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) regulates C2CD2L (Gene) and C2CD2L (Gene) is upregulated by Ruxolitinib (Compound)